Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NBI-98854

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

valbenazine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
The vesicular monoamine transporter 2 (VMAT2) is an integral presynaptic protein that regulates the packaging and subsequent… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2017
Highly Cited
2017
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
OBJECTIVE Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics… Expand
Is this relevant?
2017
2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… Expand
Is this relevant?
2017
2017
Pharmacologic Characteristics of Valbenazine (NBI-98854) and its Metabolites (P2.025)
Objective: To characterize the pharmacology of valbenazine and its metabolites in vitro . Background: Valbenazine (NBI-98854), a… Expand
Is this relevant?
2017
2017
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
BACKGROUND The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind… Expand
  • figure 1
  • table 1
Is this relevant?
2016
2016
Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27.001)
Objective: To assess safety, tolerability and persistence of effect of valbenazine in subjects with schizophrenia or… Expand
Is this relevant?
2016
2016
KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia (PL02.003)
Objective: To assess the efficacy, safety and tolerability of valbenazine (NBI-98854) for Tardive Dyskinesia (TD). Background… Expand
  • figure 2
Is this relevant?
2016
2016
A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2 (S27.007)
Objective: To assess efficacy, safety and tolerability of valbenazine for Tardive Dyskinesia (TD). Background: Valbenazine is… Expand
Is this relevant?
2015
2015
NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study
BACKGROUND Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE